Free Trial

Basel Medical Group (BMGL) Competitors

Basel Medical Group logo
$1.20 +0.02 (+1.69%)
As of 09:51 AM Eastern

BMGL vs. TOI, AIRS, DCGO, EUDA, CORBF, XGN, ATPC, SERA, KDLY, and QIPT

Should you be buying Basel Medical Group stock or one of its competitors? The main competitors of Basel Medical Group include Oncology Institute (TOI), AirSculpt Technologies (AIRS), DocGo (DCGO), EUDA Health (EUDA), Global Cord Blood (CORBF), Exagen (XGN), Agape ATP (ATPC), Sera Prognostics (SERA), Kindly MD (KDLY), and Quipt Home Medical (QIPT). These companies are all part of the "healthcare" industry.

Basel Medical Group vs.

Basel Medical Group (NASDAQ:BMGL) and Oncology Institute (NASDAQ:TOI) are both small-cap services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.

36.9% of Oncology Institute shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Oncology Institute had 2 more articles in the media than Basel Medical Group. MarketBeat recorded 5 mentions for Oncology Institute and 3 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 0.95 beat Oncology Institute's score of 0.13 indicating that Basel Medical Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Basel Medical Group
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oncology Institute
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oncology Institute has a consensus target price of $7.00, suggesting a potential upside of 133.10%. Given Oncology Institute's stronger consensus rating and higher probable upside, analysts plainly believe Oncology Institute is more favorable than Basel Medical Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Basel Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oncology Institute
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Basel Medical Group has a net margin of 0.00% compared to Oncology Institute's net margin of -17.63%. Basel Medical Group's return on equity of 0.00% beat Oncology Institute's return on equity.

Company Net Margins Return on Equity Return on Assets
Basel Medical GroupN/A N/A N/A
Oncology Institute -17.63%-186.83%-34.58%

Basel Medical Group has higher earnings, but lower revenue than Oncology Institute.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Basel Medical Group$10.05M2.20N/AN/AN/A
Oncology Institute$403.15M0.56-$83.07M-$0.70-4.29

Oncology Institute received 5 more outperform votes than Basel Medical Group when rated by MarketBeat users.

CompanyUnderperformOutperform
Basel Medical GroupN/AN/A
Oncology InstituteOutperform Votes
5
71.43%
Underperform Votes
2
28.57%

Summary

Oncology Institute beats Basel Medical Group on 8 of the 13 factors compared between the two stocks.

Get Basel Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for BMGL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMGL vs. The Competition

MetricBasel Medical GroupServices – Health IndustryServices SectorNASDAQ Exchange
Market Cap$22.15M$16.58M$2.72B$8.28B
Dividend YieldN/AN/A0.32%4.10%
P/E RatioN/AN/A5.2919.58
Price / Sales2.202.3113.63119.65
Price / CashN/AN/AN/A34.62
Price / BookN/AN/A0.214.47
Net IncomeN/A-$40,000.00-$4.34M$248.22M
7 Day Performance-49.37%-7.81%-5.13%-1.32%
1 Month Performance-72.73%-11.89%-7.34%10.73%
1 Year PerformanceN/AN/A29.22%8.40%

Basel Medical Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMGL
Basel Medical Group
N/A$1.20
+1.7%
N/AN/A$22.15M$10.05M0.0036News Coverage
TOI
Oncology Institute
2.2391 of 5 stars
$3.00
-1.5%
$7.00
+133.7%
+424.5%$227.06M$393.41M-3.85660Insider Trade
AIRS
AirSculpt Technologies
0.4304 of 5 stars
$3.65
+2.8%
$3.75
+2.7%
+24.2%$214.55M$172.10M-26.07240Gap Up
DCGO
DocGo
3.8035 of 5 stars
$1.50
+6.8%
$3.56
+138.1%
-55.5%$152.47M$520.50M5.342,920
EUDA
EUDA Health
N/A$3.92
-0.9%
N/A+57.2%$145.45M$4.01M0.002News Coverage
Positive News
Gap Down
CORBF
Global Cord Blood
N/A$1.05
-3.7%
N/A-29.2%$127.63M$196.12M0.001,200Gap Up
XGN
Exagen
4.1048 of 5 stars
$5.78
+0.7%
$7.50
+29.8%
+222.5%$123.11M$56.72M-6.15220
ATPC
Agape ATP
0.4386 of 5 stars
$1.97
+31.3%
N/A-56.6%$98.46M$1.32M-2.7040Analyst Upgrade
Gap Down
SERA
Sera Prognostics
1.4833 of 5 stars
$2.37
-0.8%
N/A-77.1%$89.26M$115,000.00-2.39120Positive News
KDLY
Kindly MD
1.0533 of 5 stars
$12.50
-9.8%
N/AN/A$72.52M$2.47M-15.64N/AGap Up
QIPT
Quipt Home Medical
1.691 of 5 stars
$1.41
-7.0%
$4.43
+214.9%
-45.5%$60.46M$244.72M-8.25800Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:BMGL) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners